IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (Nasdaq:ELGX), the developer and manufacturer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today revised 2007 product revenue guidance to $27 million to $29 million, representing an increase of 87% to 101% compared with 2006 product revenue. The Company also increased 2007 gross margin guidance to 60% to 62%, and expects operating expenses to range from $32 million to $34 million.
